Most type II diabetics have elevated insulin and insulin-like growth factor (IGF)-1 levels at baseline, which are mitogenic to tumor cells via activation of downstream signaling cascades that mediate proliferation, migration/invasion, angiogenesis, and treatment resistance. Here, INS is linked to neoplasm.